公开(公告)号：US11091517B2

公开(公告)日：2021-08-17

申请号：US16631141

申请日：2018-07-18

Applicant: TOKUSHIMA UNIVERSITY ,  ONCOTHERAPY SCIENCE, INC.

Inventor： Toyomasa Katagiri ,  Tetsuro Yoshimaru ,  Takashi Miyamoto ,  Yasuhide Okamoto

IPC: C07K7/08 ,  A61K47/65 ,  A61P35/00 ,  A61K38/00

Abstract: The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.

公开(公告)号：US20210030823A1

公开(公告)日：2021-02-04

申请号：US16964142

申请日：2019-01-25

Applicant: TOKUSHIMA UNIVERSITY ,  JICHI MEDICAL UNIVERSITY ,  GENE THERAPY RESEARCH INSTITUTION CO., LTD.

Inventor： Kohji ITOH ,  Daisuke TSUJI ,  Shinichi MURAMATSU ,  Katsuhito ASAI

IPC: A61K35/76 ,  C12N7/00 ,  A61P25/28

Abstract: According to a conventional method for treatment of Sandhoff disease and Tay-Sachs disease comprising administering a modified β-subunit to a patient in the form of a protein, it is necessary that administration be performed frequently. This invention relates to a recombinant adeno-associated virus virion comprising: capsomere comprising a protein capable of forming a virus virion; and a polynucleotide packaged in the capsomere comprising a promoter sequence and nucleotide sequences operably linked to the promoter sequence encoding a first amino acid sequence derived from the amino acid sequence of the β-subunit of wild-type human β-hexosaminidase composed of amino acids 55 to 556 in the sequence as shown in SEQ ID NO: 28 by substitution of amino acids 312 to 318 with glycine, serine, glutamic acid, proline, serine, glycine, and threonine in that order and a second amino acid sequence, which is an amino acid sequence of a signal peptide linked to the N terminus of the first amino acid.

公开(公告)号：US10383822B2

公开(公告)日：2019-08-20

申请号：US14420544

申请日：2013-08-09

Applicant: Taiho Pharmaceutical Co., Ltd. ,  The University of Tokushima

Inventor： Yusuke Doi ,  Tatsuhiro Ishida

IPC: A61K45/06 ,  A61K47/22 ,  A61K9/127 ,  A61K31/282 ,  A61K31/555

Abstract: An object of the present invention is to provide an oxaliplatin-encapsulating liposome aqueous dispersion that has excellent long-term storage stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, the oxaliplatin-encapsulating liposome aqueous dispersion containing 2-morpholinoethanesulfonic acid in an external aqueous phase.

公开(公告)号：US10371630B2

公开(公告)日：2019-08-06

申请号：US14909424

申请日：2014-07-18

Applicant: TOKUSHIMA UNIVERSITY ,  FUJIKIN INCORPORATED

Inventor： Yoshihiro Deguchi ,  Masaaki Nagase ,  Nobukazu Ikeda ,  Michio Yamaji

IPC: G01N21/31 ,  G01N21/33 ,  G01N21/59 ,  G01N21/84 ,  G01N21/85

Abstract: An inline concentration meter includes a light source unit emitting mixed light containing at least two wavelengths with a phase difference, a detecting unit including a light incident part for entering the mixed light emitted from the light source unit into a fluid passage of a detector body and at least two light detection parts receiving the mixed light passed through the fluid passage, a computing processor unit conducting frequency analyzes of detection signals of the mixed light output from the respective light detection parts and computing variations of intensities of the detection signals corresponding to absorbances in at least two frequency ranges to compute a concentration of fluid in the fluid passage based on the variations of the intensities of the detection signals, and a recording/displaying unit recording and displaying a value of the fluid concentration computed at the computing processor unit.

公开(公告)号：US20190049368A1

公开(公告)日：2019-02-14

申请号：US16068087

申请日：2016-12-20

Applicant: TOKUSHIMA UNIVERSITY

Inventor： Yoshihiro Deguchi

IPC: G01N21/27 ,  G01N21/39

CPC classification number: G01N21/27 ,  G01N21/031 ,  G01N21/3504 ,  G01N21/39

Abstract: A gas analysis device includes a laser light source configured to output a laser beam, an irradiation unit configured to irradiate a measurement region including measurement target gas with the laser beams in plural directions, plural photoreceivers each configured to receive a laser beam having passed through the measurement region and output an electric signal according to intensity of the received laser beam, and an analyzer configured to analyze the physical state of the measurement target gas based on the electric signal output from each photoreceiver. The analyzer sets a function (e.g. two-dimensional polynomial f(X,Y)) representing the physical state (e.g. concentration, temperature) of the target gas at least in the measurement region, and measures the physical state of the target gas by determining a coefficient of each of terms included in the function based on a measured value obtained from the electric signal output from the photoreceiver.

公开(公告)号：US20190023739A1

公开(公告)日：2019-01-24

申请号：US16070896

申请日：2017-01-16

Applicant: TOKUSHIMA UNIVERSITY ,  ONCOTHERAPY SCIENCE, INC.

Inventor： TOYOMASA KATAGIRI ,  TAKASHI MIYAMOTO ,  RIE HAYASHI

IPC: C07K7/04 ,  A61P35/00

Abstract: The present invention provides peptides containing a structure in which a portion of the dominant negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 is substituted with stapling structure(s). Peptides of the present invention have excellent cell growth inhibitory actions. Furthermore, their cell growth inhibitory actions continue for a longer time than the actions of peptides without stapling structures. Therefore, these peptides have features suitable for clinical applications in cancer therapy.

公开(公告)号：US09651467B2

公开(公告)日：2017-05-16

申请号：US14888841

申请日：2014-04-30

Applicant: TOKUSHIMA UNIVERSITY ,  FUJIKIN INCORPORATED

Inventor： Yoshihiro Deguchi ,  Masaaki Nagase ,  Ryousuke Dohi ,  Nobukazu Ikeda ,  Kouji Nishino ,  Michio Yamaji ,  Tadayuki Yakushijin

IPC: G01N9/00 ,  G01N21/05 ,  G01N21/59 ,  G01N9/24 ,  G01N21/33 ,  G01N21/85

CPC classification number: G01N9/00 ,  G01N9/24 ,  G01N21/05 ,  G01N21/33 ,  G01N21/59 ,  G01N21/85 ,  G01N2201/08

Abstract: This invention is related to an optical-analysis-type raw material fluid density detector including a detector main body and a light oscillation unit and a light detection unit that are provided on the upper surface or the under surface of the detector main body, in which the detector main body has at least one recess formed in the upper surface and the under surface, a fluid flow path connecting a fluid inlet of the detector main body to the recess, a fluid flow path connecting the recesses to each other, and a fluid flow path connecting the recess to a fluid outlet of the detector main body; the light oscillation unit is disposed in the recess that is closest to the inlet; and light detection units are disposed in the remaining recesses.

公开(公告)号：US09540420B2

公开(公告)日：2017-01-10

申请号：US13582160

申请日：2011-03-01

Applicant: Hiroshi Kido ,  Dai Mizuno

Inventor： Hiroshi Kido ,  Dai Mizuno

IPC: A61K39/395 ,  C07K14/005 ,  A61K9/00 ,  A61K39/145 ,  A61K39/12 ,  A61K39/00 ,  A61K47/32

CPC classification number: C07K14/005 ,  A61K9/0043 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K47/32 ,  A61K2039/541 ,  A61K2039/543 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  C12N2760/16122 ,  C12N2760/16134 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/396 ,  Y02A50/466

Abstract: A mucosal vaccine producing an antigen-specific mucosal IgA and a blood IgG in the levels capable of exerting an effective immune induction and an infection-preventing effect, which comprises: (a) an AD vehicle consisting of a synthetic peptide and a lipid(s), wherein the synthetic peptide consisting of the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20); (b) a carboxylvinyl polymer; and, (c) an antigenic protein, in an amount incapable of producing a sufficient mucosal IgA and blood IgG for exerting an effective immune induction and an infection-preventing effect when used by itself. The mucosal vaccine of the invention has an antibody producing ability which is more potent than those of mucosal vaccines of the prior art, and as a result it can exert an excellent effect even with an extremely small amount of an antigen.

Abstract translation: 本发明的粘膜疫苗具有比现有技术的粘膜疫苗更有效的抗体生成能力，结果即使使用极少量的抗原也能发挥优异的效果。

公开(公告)号：US09393554B2

公开(公告)日：2016-07-19

申请号：US14654996

申请日：2014-02-04

Applicant: TOKUSHIMA UNIVERSITY ,  MITSUBISHI RAYON CO., LTD.

Inventor： Shigeru Sugiyama ,  Yuuki Katou ,  Toshiya Yasukawa ,  Shuji Akihara ,  Wataru Ninomiya

IPC: C07C45/51 ,  B01J29/03 ,  B01J35/10 ,  B01J29/035 ,  C07C45/52 ,  C07C47/02

CPC classification number: B01J29/0308 ,  B01J29/035 ,  B01J35/1061 ,  C07C45/52 ,  C07C47/02

Abstract: Provided is a method that produces a saturated aldehyde from a 1,2-alkanediol in high yield. Disclosed is a method for producing a saturated aldehyde from a 1,2-alkanediol in the presence of a regular mesoporous material.

Abstract translation: 提供了以高产率从1,2-链烷二醇生产饱和醛的方法。 公开了一种在常规介孔材料存在下由1,2-链烷二醇生产饱和醛的方法。

公开(公告)号：US09278133B2

公开(公告)日：2016-03-08

申请号：US12447351

申请日：2007-10-26

Applicant: Tetsuhiro Harakawa ,  Hirotoshi Nakano ,  Yasushi Torii ,  Yoshitaka Goto ,  Miho Shinmura ,  Sachio Okuda ,  Ryuji Kaji ,  Shunji Kosaki

Inventor： Tetsuhiro Harakawa ,  Hirotoshi Nakano ,  Yasushi Torii ,  Yoshitaka Goto ,  Miho Shinmura ,  Sachio Okuda ,  Ryuji Kaji ,  Shunji Kosaki

IPC: A61K38/48 ,  A61K39/08 ,  A61K9/00 ,  A61K47/42 ,  A61K9/19

CPC classification number: A61K47/42 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/4893 ,  Y02A50/469

Abstract: A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional known botulinum toxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.

Abstract translation: 提供了一种新型的A型肉毒杆菌毒素制剂。 一种包含作为活性成分的来自肉毒梭菌的高度纯化的A型肉毒杆菌毒素作为婴儿肉毒杆菌病原体的神经肌肉阻滞剂和用于治疗肌肉过度活动的疾病的药物，其包含所述毒素作为活性成分。 特别地，与常规已知的肉毒杆菌毒素制剂相比，本发明的药物具有快速的潜力和较少的扩散作用，因此具有较宽的安全性，可用作减少局部，肌肉过度活动的治疗药物 在肌肉过度活动的疾病中。